Research programme: GlycoPEGylated proteins - Novo Nordisk

Drug Profile

Research programme: GlycoPEGylated proteins - Novo Nordisk

Latest Information Update: 14 Jan 2010

Price : $50

At a glance

  • Originator Neose Technologies; Novo Nordisk
  • Class Glycoproteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Haemophilia A; Haemophilia B

Most Recent Events

  • 08 Feb 2008 Preclinical development is ongoing
  • 21 Dec 2005 Neose Technologies and Novo Nordisk expand a research, development and license agreement
  • 17 Nov 2003 Early research in Haemophilia A in Denmark (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top